(Q71479805)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

title

Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

author name string

A Fredriksson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

T Archer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

publication date

1 January 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

page(s)

19-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

Deprenyl alters behavior and caudate dopamine through an amphetamine-like action

18 October 2019

cites work

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

12 December 2020

MPTP-induced behavioural and biochemical deficits: a parametric analysis

1 reference

12 December 2020

Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease

1 reference

12 December 2020

3-o-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway.

1 reference

12 December 2020

The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease

1 reference

12 December 2020

Selegiline and cognitive function in Parkinson's disease

1 reference

12 December 2020

L-deprenyl treatment of on-off phenomena in Parkinson's disease

1 reference

12 December 2020

MPTP-induced hypoactivity in mice: reversal by L-dopa.

1 reference

12 December 2020

Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys

1 reference

12 December 2020

Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues

1 reference

12 December 2020

A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset

1 reference

12 December 2020

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.

1 reference

12 December 2020

Long-term side-effects of levodopa.

1 reference

12 December 2020

Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group

1 reference

12 December 2020

Deprenyl in Parkinson's disease

1 reference

12 December 2020

Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease

1 reference

12 December 2020

Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study

1 reference

12 December 2020

Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase

1 reference

12 December 2020

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease

1 reference

12 December 2020

18F‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462)

1 reference

12 December 2020

Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats

1 reference

12 December 2020

Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease

1 reference

12 December 2020

(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease

1 reference

12 December 2020

Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats

1 reference

12 December 2020

Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse

1 reference

12 December 2020

Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.

1 reference

12 December 2020

Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.

1 reference

12 December 2020

Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping

1 reference

12 December 2020

Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences.

1 reference

12 December 2020

Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats

1 reference

12 December 2020

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

1 reference

12 December 2020

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

1 reference

12 December 2020

Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency

1 reference

12 December 2020

3-O-methyldopa blocks dopa metabolism in rat corpus striatum.

1 reference

12 December 2020

The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

1 reference

12 December 2020

Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

1 reference

12 December 2020

Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats

1 reference

12 December 2020

[The effect of chronic treatment of deprenyl in animal models of Parkinson's disease]

1 reference

12 December 2020

Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons

1 reference

12 December 2020

L-dopa therapy in Parkinson's disease: a critical review of nine years' experience

1 reference

12 December 2020

R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron

1 reference

12 December 2020

Catechol-O-methyltransferase and Parkinson's disease

1 reference

12 December 2020

The pharmacology of selegiline ((-)deprenyl). New aspects

1 reference

12 December 2020

The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers

1 reference

12 December 2020

Deprenyl is metabolized to methamphetamine and amphetamine in man

1 reference

12 December 2020

(-)Deprenyl (selegiline) is devoid of amphetamine-like behavioural effects in rats

1 reference

12 December 2020

The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

1 reference

12 December 2020

Pharmacokinetics and metabolism of selegiline.

1 reference

12 December 2020

Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease

1 reference

12 December 2020

Effects of 3-OM-dopa on monoamine metabolism in rat brain

1 reference

12 December 2020

Behavioral effects of deprenyl in aged rats

1 reference

12 December 2020

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

12 December 2020

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

1 reference

12 December 2020

Selegiline in Parkinson's disease

1 reference

12 December 2020

Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration

1 reference

12 December 2020

A review of the pharmacology of selegiline

1 reference

12 December 2020

Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases

1 reference

12 December 2020

3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease

1 reference

12 December 2020

Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat.

1 reference

12 December 2020

1 reference

12 December 2020

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

12 December 2020

New approaches to the treatment of age-related brain disorders

1 reference

12 December 2020

Further proof that (−) deprenyl fails to facilitate mesolimbic dopaminergic activity

1 reference

12 December 2020

Dissociation between biochemical and behavioral recovery in MPTP-treated mice

1 reference

12 December 2020

3-O-methyldopa and the response to levodopa in Parkinson's disease

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01276562

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8785021%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

1 reference